PRECISION BIOSENSOR, INC. Precision Biosensor, Inc. Stock
Equities
A335810
KR7335810008
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,070 KRW | +0.25% |
|
-7.08% | -14.68% |
| Sales 2022 | 20.46B 14.87M | Sales 2023 | 20.39B 14.82M | Capitalization | 55.4B 40.28M |
|---|---|---|---|---|---|
| Net income 2022 | -6.81B -4.95M | Net income 2023 | -4.49B -3.26M | EV / Sales 2022 | 3.74 x |
| Net Debt 2022 | 7.9B 5.75M | Net Debt 2023 | 13.78B 10.02M | EV / Sales 2023 | 3.39 x |
| P/E ratio 2022 |
-10
x | P/E ratio 2023 |
-12.3
x | Employees | 102 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 59.38% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.25% | ||
| 1 week | -7.08% | ||
| Current month | -16.60% | ||
| 1 month | -16.34% | ||
| 3 months | -23.93% | ||
| 6 months | -20.20% | ||
| Current year | -14.68% |
1 week
4 055.00
4 360.00
1 month
4 055.005 350.00
Current year
4 055.006 350.00
1 year
4 055.007 300.00
3 years
4 055.0019 800.00
5 years
4 055.0041 000.00
10 years
4 055.0041 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Han-Sin Kim
CEO | Chief Executive Officer | 56 | 18-04-30 |
Seung-Hoon Lee
DFI | Director of Finance/CFO | 51 | 18-12-31 |
Jong-Myeon Park
CTO | Chief Tech/Sci/R&D Officer | 51 | 18-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hak-Hyun Nam
BRD | Director/Board Member | 64 | - |
Jung-Wook Seo
BRD | Director/Board Member | 62 | - |
Han-Sin Kim
CEO | Chief Executive Officer | 56 | 18-04-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-28 | 4,070 | +0.25% | 8 247 |
| 24-04-26 | 4,060 | -1.10% | 16,978 |
| 24-04-25 | 4,105 | -2.61% | 14,429 |
| 24-04-24 | 4,215 | +1.44% | 16,407 |
| 24-04-23 | 4,155 | -1.07% | 17,341 |
End-of-day quote Korea S.E., April 28, 2024
More quotes
PrecisionBiosensor Inc is a Korea-based company mainly engaged in the development, manufacture and sale of in vitro diagnostic reagents. The Company's main products include testers and cartridges. The testers are portable immunoassay diagnostic devices for on-site diagnosis that uses colorimetric and time-resolved fluorescence to check acute heart disease, metabolism, and inflammatory diseases. The cartridges are used in gold absorption and time-resolved fluorescence analysis diagnostic equipment, and can check acute heart disease, metabolism, and inflammatory diseases. The Company sells its products in domestic and overseas markets such as Europe, China, the Middle East, and Southeast Asia.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -14.68% | 34.26M | |
| +1.69% | 12.8B | |
| -7.57% | 7.61B | |
| +3.22% | 5.41B | |
| +0.93% | 4.51B | |
| +9.73% | 4.49B | |
| +9.21% | 2.73B | |
| -13.87% | 2.02B | |
| -11.63% | 1.73B | |
| +0.55% | 1.64B |
- Stock Market
- Equities
- A335810 Stock
